Literature DB >> 3037987

Adrenoleukodystrophy: dietary oleic acid lowers hexacosanoate levels.

W B Rizzo, M W Phillips, A L Dammann, R T Leshner, S S Jennings, J Avigan, V K Proud.   

Abstract

Adrenoleukodystrophy (ALD) is an X-linked disorder characterized by demyelination, adrenal insufficiency, and accumulation of saturated very-long-chain fatty acids (VLFA), particularly hexacosanoate (C26:0). We treated 5 patients with adrenoleukodystrophy (3 males and 2 symptomatic female carriers) for 6 months with a diet enriched in oleic acid (C18:1) and moderately restricted in C26:0. Elevated plasma and erythrocyte levels of C26:0 decreased in a time-dependent manner during treatment. Total plasma C26:0 concentration was lowered by 50 +/- 9% (p less than 0.01); it became normal in the female carriers. The total erythrocyte level of C26:0 decreased (44 +/- 5%; p less than 0.001) into the normal range in all patients. Significant decreases were noted in the saturated VLFA composition of plasma and erythrocyte sphingomyelin and erythrocyte phosphatidylcholine during dietary treatment. In general, decreases in saturated VLFA levels were accompanied by increases in monounsaturated VLFA levels, while total VLFA values did not change. This novel approach to the treatment of adrenoleukodystrophy, in which there is an exchange of monounsaturated VLFA for the more toxic saturated VLFA, may prove clinically beneficial in this disorder.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3037987     DOI: 10.1002/ana.410210304

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  19 in total

1.  Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".

Authors:  B M van Geel; J Assies; E B Haverkort; J H Koelman; B Verbeeten; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  X-linked adrenoleukodystrophy: first report of the Italian Study Group.

Authors:  A Di Biase; S Salvati; C Avellino; M Cappa; E Bertini; I Moroni; M Rimoldi; G Uziel
Journal:  Ital J Neurol Sci       Date:  1998-10

Review 3.  X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.

Authors:  B M van Geel; J Assies; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

4.  Glycerol trioleate/glycerol trierucate therapy in X-linked adrenoleukodystrophy: saturated and unsaturated fatty acids in blood cells. Implications for the follow-up.

Authors:  M Ruiz; T Pampols; M Girós
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

Review 5.  The inborn errors of peroxisomal beta-oxidation: a review.

Authors:  R J Wanders; C W van Roermund; R B Schutgens; P G Barth; H S Heymans; H van den Bosch; J M Tager
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

6.  A new therapeutic approach for X-linked adrenoleukodystrophy.

Authors:  M Cappa; E Bertini; M Di Capua; M Rimoldi; G Uziel
Journal:  Eur J Pediatr       Date:  1990-05       Impact factor: 3.183

7.  Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's oil).

Authors:  M Rasmussen; A B Moser; J Borel; S Khangoora; H W Moser
Journal:  Neurochem Res       Date:  1994-08       Impact factor: 3.996

8.  Thrombocytopenia induced by erucic acid therapy in patients with X-linked adrenoleukodystrophy.

Authors:  S Zierz; R Schröder; C J Unkrig
Journal:  Clin Investig       Date:  1993-10

Review 9.  Adrenoleukodystrophy: phenotypic variability and implications for therapy.

Authors:  H W Moser; A B Moser; K D Smith; A Bergin; J Borel; J Shankroff; O C Stine; C Merette; J Ott; W Krivit
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

Review 10.  The inherited leukodystrophies: a clinical overview.

Authors:  J Aicardi
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.